Drugmakers hike US prices on 350 medicines despite pressure from Trump | REUTERS

Key Concepts

• List Price: The official price of a drug before any discounts or rebates.
• Rebates: Payments made by drug manufacturers to Pharmacy Benefit Managers (PBMs) and other intermediaries.
• Pharmacy Benefit Managers (PBMs): Companies that manage prescription drug benefits on behalf of health insurers.
• Medicare Negotiation: The recent US government initiative allowing Medicare to negotiate lower drug prices for certain medications.
• Inflation Rate: The rate at which the general level of prices for goods and services is rising, and used as a benchmark for price adjustments.

Planned Drug Price Increases in 2026

Drug manufacturers are planning to increase the list prices of at least 350 branded medications in the United States in 2026, as reported by data exclusively provided to Reuters by healthcare research firm Three Access Advisors. This includes increases for vaccines and significant cancer treatments, specifically mentioning the IB brand of cancer drugs. This move occurs despite ongoing pressure from the Trump administration to lower drug costs. The number of planned price increases represents an increase compared to the same period last year.

Price Hike Details & Context

While the median price increase is projected to be 4%, consistent with 2025 levels, this figure does not account for rebates offered to Pharmacy Benefit Managers (PBMs) or other discounts. This means the actual cost to patients may be different, but the initial list price – the starting point for many insurance calculations – is rising. Approximately nine drugs are slated for list price decreases, with Jardiance, a diabetes treatment, experiencing a substantial 40% reduction. This reduction is directly linked to the US government’s recent negotiation of lower prices for Medicare beneficiaries (those aged 65 and older) beginning in 2026.

Limited Impact of Medicare Negotiation

Despite the announcement of these negotiated price reductions, a health policy researcher interviewed by Reuters characterized the impact as minimal. The researcher stated, “These deals are being announced as transformative when in fact they really just nibble around the margins in terms of what is really driving high prices for prescription drugs in the US.” This suggests the negotiated reductions, while positive, are insufficient to address the broader issue of high drug costs in the US.

US Drug Prices Compared to Other Nations

The report highlights the significantly higher cost of prescription drugs in the United States compared to other developed nations. US patients currently pay, on average, nearly three times more for the same medications than patients in other developed countries. This disparity underscores the ongoing affordability challenges faced by American consumers.

Pfizer’s Price Adjustments

Pfizer is planning the largest number of list price increases, affecting approximately 80 different drugs. This includes increases for its cancer drug, IB brands, and its COVID-19 vaccine, which will see a 15% price increase. However, Pfizer released a statement asserting that the average list price adjustment for its innovative medicines and vaccines for 2026 will remain below the overall rate of inflation.

Timing and Future Expectations

Drug makers historically announce price changes in early January, making it the most significant month for price adjustments. Further price increases and cuts are therefore anticipated in the coming weeks.

Synthesis

The data reveals a complex landscape of drug pricing in the US. While some price reductions are occurring due to Medicare negotiation, a substantial number of drugs are facing list price increases. The lack of transparency regarding rebates and discounts, coupled with the significantly higher cost of drugs in the US compared to other developed nations, continues to pose a significant challenge to affordability and access. The impact of the Medicare negotiation program appears limited, prompting concerns that more substantial reforms are needed to address the root causes of high prescription drug prices.